Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Ghassan El‐Haddad et al.|New England Journal of Medicine|2017Cited by 3.2k
Gastroenteropancreatic neuroendocrine tumoursIrvin M. Modlin, Anders Sundin, Kjell Öberg et al.|The Lancet Oncology|2008Cited by 1.8k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryRamón Salazar, Éric Baudin, Anne Couvelard et al.|Neuroendocrinology|2012Cited by 869
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsM. Caplin, Zeng Zheng-Pei, Éric Baudin et al.|Annals of Oncology|2015Cited by 698
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388